Cargando…
MnDPDP: Contrast Agent for Imaging and Protection of Viable Tissue
The semistable chelate manganese (Mn) dipyridoxyl diphosphate (MnDPDP, mangafodipir), previously used as an intravenous (i.v.) contrast agent (Teslascan™, GE Healthcare) for Mn-ion-enhanced MRI (MEMRI), should be reappraised for clinical use but now as a diagnostic drug with cytoprotective propertie...
Autores principales: | Jynge, Per, Skjold, Arne M., Falkmer, Ursula, Andersson, Rolf G. G., Seland, John G., Bruvold, Morten, Blomlie, Viggo, Eidsaunet, Willy, Karlsson, Jan O. G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501573/ https://www.ncbi.nlm.nih.gov/pubmed/32994754 http://dx.doi.org/10.1155/2020/3262835 |
Ejemplares similares
-
Evidence that fodipir (DPDP) binds neurotoxic Pt(2+) with a high affinity: An electron paramagnetic resonance study
por: Stehr, Jan Eric, et al.
Publicado: (2019) -
Mangafodipir a Selective Cytoprotectant — with Special Reference to Oxaliplatin and Its Association to Chemotherapy-Induced Peripheral Neuropathy (CIPN)()()
por: Karlsson, Jan Olof G., et al.
Publicado: (2017) -
Exacerbated Neuropathy in POLAR A and M Trials Due to Redox Interaction of PledOx-Associated Mn(2+) and Oxaliplatin-Associated Pt(2+)
por: Karlsson, Jan Olof G., et al.
Publicado: (2023) -
Predicting Therapeutic Efficacy of Vascular Disrupting Agent CA4P in Rats with Liver Tumors by Hepatobiliary Contrast Agent Mn-DPDP-Enhanced MRI
por: Liu, Yewei, et al.
Publicado: (2019) -
May Mangafodipir or Other SOD Mimetics Contribute to Better Care in COVID-19 Patients?
por: Karlsson, Jan Olof G, et al.
Publicado: (2020)